Roche finds USP in cancer, inking deal with KSQ to expand stable of synthetic lethal candidates

cafead

Administrator
Staff member
  • cafead   Jul 13, 2023 at 11:42: AM
via Roche is pushing deeper into synthetic lethality. One year after paying $125 million to join the ATR race, the Swiss drug developer has secured an exclusive global license to KSQ Therapeutics’ early-phase USP1 inhibitor.

article source
 

<